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06jrctim. Thii study sought lo lcsl lbc bptbtsis lbat big 
edatbdi~-I piasmr bevels ia advanced btpr( failerr are rtlalcd to 
SUWiVSl. 
&k&gmud In bcar( failure. prad~tioa oftbc p&ml vm- 
strictor cwdotbdia-I is tocreased. &cause ckvalioa of immrmb 
re8rtlvc cdolbdb-I in severe btarl failure is primarily rekd lo 
the pmursor %g* rdolklia-I, iocrrased big d&clin-I 
levels my be associated dlb 1 poof progosls. 
hftfhds. Plasm big clnlbdhI comnhlh in ddilh 
to 16 chical, kmodynamii aad oruu4~I varbbk, were 
o&aid from I I3 pbmts (mean age [*SEMI 53 f 1 years) wilb 
left vcolrk8Lr ejcclii fraction <X6 ad wrrt rd8led tu I-year 
morwity by a stcpaisc cox lrgressia maiuvtile 8Bdysis. 
Reds. Plasm big cdotbdid coaccahlioas wtrc signifi- 
ally tGgkr in patients with mderslc and se5m brad failure 
tklr in those with mild bcarl failure (45 f 0.4 ad 6.0 * 0.1 vs. 
Selection criteria for prospective transplant candidates focus 
on New York Heart Association functional class. hemody- 
namic data (l-3) and. more rccentlp. peak oxygen consump 
tion during exercise (4). In addition, neurnhumoral variables 
such as plasma norepinephrine (5) and atrial natriuretic pep 
tides (6.7) are considered valuable to judge progression of the 
disease and were previously found to CC associated with a poor 
prognosis in d&rent dcgrccs of heart failure and left vcntric- 
ular dysfunction. 
Another recently idcntiticd hormone relating to severity of 
hcdn failure is endothelin-1. an cndothelium-dcrivcd peptidc. 
which is characterized by potent and long-labring vascconstric- 
tion. particularly in the pulmonary circulation (8-M). SEveral 
studies have reported the elevation of immunoreactivc 
endothelin-l in plzna of patients with chronic heart failure 
2.7 f 0.1 ImoUnl. p = O.oBoI. mptcliwl~ 1 ad lam in 58 
one-year survivors than in 29 noawnivwr !L6 + 0.1 vs. 5.9 2 
0.4 fmoUnl, p = 0.0001~ ad 26 kart tmnspbt rvcipkmts. By 
uaivarialc rdysis big cadulbrlia-I plasm- coaceWalioas 
tp < O-OW). fnutiwal clasr daily foroswidr dose. kn vcn1ric- 
uhrejmliosJfradimmcJsl~v*d~ 
atlid usltriurctic peptide, sodim J&II activity and aklosll?lwu 
kvclswcvcaIlrdaIed10lmrtdify.k1dyfwlkmalcl8ss 
pvwilkduddilimd pmgrosl&idolmalioavvkmhigrmblMi,1 
p(8Sm ItvtlS *ttC cWefud irtu lk n dlivark mud& 
c * * _r1nadvMtailswthihrr,plsrlbig-1 
is slmugly rrlalcd to w-vival ad appars to pdii I--yar 
-lily betW thu wait v8M aod kvds of atrid 
utriurrlic peptide. au csl&!iskd aeuroLs~l ProgMtic 
aarkr in cbvdc hew-l frilmrr. 
rJ Am Cd Cadid 19%:27:63-*-1!) 
(I I-151. but only in one study were mature ?I-amrn+acid 
cndothclin-I and its biologically le\s active precursor. called 
big cndothelin-I. measured separately. By I!% approach it was 
demonstrated that ~bc elevation of plasma endothclin-I in 
severe heart failure is primarily related to elevated circulating 
hip endothelin-I (16). It is well recognized that endothelin-1 
posse-5 potentially harmful pathophysiolgic properties 
(H.Y.17.1X) and that it may fun&m as marker of the degree of 
left ventricular wfun.lion and subsequent elevation in filling 
prcssurc (10.14). Bccau9z asymptomatic left ventricular dys- 
function is devoid of increased mdothelin-l pLuma levels ( 16). 
its increased appearance in the peripherdl circulation of pa- 
tients with chronic heart failure shtuid hz associated with a 
prior prognosis in advakvd disease. Of importance. it was 
recently reported hy Omland et al. (IY) that determination of 
endothclin-I plasma levels in the subacute phase of myocardial 
infarction proved useful to predict death after acute myucar- 
dial infarction. 
The aim of the present study was to further investigate the 
relationship among circulating big cndothelin-I plasma levels- 
functional class and alter&m in cardiac hemodynamics in 
scverc heart failure and to tcs~ ihe hypothesis that the concvn- 
tration of big endothelin-I in plasma may wvc as another 
noninvasive marker of mortality in patients with advanced 
disease. Furthermore. WC aimed to compare the predictive 
power of plasma big endothelin-I determination with that of 
hemodynamic measurements and with plasma atria1 narriurctic 
peptide determination, a variable previously found to bc 
superior to norcpinephrine plasma levels in predicting death 
from chronic hean failure (6). 
Methods 
!%udy desfga and pntieMs. Venous blood for actermina- 
tion of bigendothelin-I, atrial natriurctic peptidc. norepincph- 
rine, plasma renin activity and aldosterone was prospectively 
obtained from I I3 consecutive patients with congestive heart 
failure admitted to our center between lYg9 and 1992 (97 men, 
16 women; meal1 [?SEM] age 53 2 I years, rauge 21 to 73). 
The cause of heart failure was invasively diagnosed dilated 
cardiipathy in 83 patients and ischemic heart disease in 
30. All patients had a left ventricular ejection fraction of LXl% 
by radioouchde ventriculography. At the beginning of the study, 
SO patients were in New York Heart Association functional class 
11, 42 in class III and 21 in class IV. At the time of study all 
patients were taking digitalis. diuretic drug and varying doses of 
the angioterrsinconverting enzyme inhibitor captopril. Patient 
and treatment data a~ sham in Table I. Baseline clinical 
examinations, blood sampling for laboratory variables and 
right heart catheterization were performed on rhe same day. 
The study end point was predefined at I2 months. Patients 
were subsequently stratified into those who survived (n = 
58), received a heart transplant (n = 26) or died of 
progressive hean faiturc within the study period (n = 29). 
Big endothelin-1 and other neurohumoral plasma levels 
were not available to the clinician and did not influence 
patlent management either with regard to medication or as 
prioritization for heart transplantation. 
Bkmd sampling procedures and hormonal assays. Venous 
blood samples were drawn after at lcast 30 min of rest from an 
indwelling catheter for determination of routine laboratory 
variahles as well as baseline levels of big endothelin-I, norepi- 
nephrine. atrial natriuretic peptidc, aidosterone and plasma 
rcnin a&v@. Test tubes were placed on ice and centrifuged 
immediately. Plasma samples were stored at -7(PC until 
analyzed. 
Olg end&e/in. Endothelin in plasma was measured as 
immunoreactive big endothelin-I (C-terminal fragment big 
endothelin- I ) by an extraction-based radioimmunoassay (Bio- 
mcdica) as described in detail elsewhere (20). In brief, the 
prptides are extracted from ethylenediaminetetraacetic acid 
(EDTA) plasma by SepPack C,, cartridges and desorbed by 
methanol/water/trifluoroacetic acid (&I : 20 : (I. I by volume). 
The eluate is dried by vacuum concentration, dissolved in assay 
buffer and used for radioimmunoassay. The big endothelin 
radioimmunoassay system is a nonequilibrium radioimmuno- 
assay with delayed addition of iodine125 big endothelin-1 
tracer and second antibody separation of bound from unbound 
ligand. The antibody has heen raised against C-terminal 
fragment hig endothelin-l and has 100% reactivity with 
big endothelin-I, 829 with a C-terminal fragment of big 
endothelin-I and <I% with endothelin-I,23 and atrial natri- 
uretic pcptide. 
The sensitivity of the assay is 0.7 fmol/ml; the linear range 
of the calibration curve, with an intraassay precision 4% and 
an inlcrassay precision <I3% (coetienu of variation), ex- 
tends from I to I7 fmol/ml. SpeciEcity of the big endothelin 
radioimmunoassay was tested by determination of the endog- 
enous peptides in the extracts from ethylenediaminctetra- 
acetate plasma samples before and after separation by high 
prcssurc liquid chromatngraphv of the extracts. The sum of the 
immunoreactivity of the peptidcs wparated by high-prcssurc 
liquid chromatography was identical within the limit of error 
to the ;mmunorcactivity obtained hy direct assay of the 
cxtrdction. Our reference range is 0.8 to I.8 fmol/ml. Big 
cndothelin-1 and C-terminal big endothtlin-I arc different in 
molecular weight. Our assay quantifies the sum of both forms 
without discrimination between thz peptides. Therefor:. re- 
sults are expressed on a molar basis (fmol/ml). 
f!avnu rrrrirr octirip was mcasurcd hy a commcrcizl rddio- 
immunoassay (Clinical Assays, lncstar Corp.) with assay sen- 
sitivity 0.02 nglml per h and specificity IUlq for anglotensin I 
and 0.029 for a synthetic renin substrate (tctradecapept&). 
The normal range is 0.8 to 2.0 @ml per h. 
Plasma a/dos/mw was measured by a commercial radio- 
immunoassay (Sorin. Biomcdica) with sensitivity 15 pg/ml and 
specificity IWX- for aldostcrone and 4.2% for Sbeta-S-alpha- 
tetrahydroaldosterone. The normal range is 35 to .300 p&ml. 
Ahblnatriumirprptide was measured from trasylol-EDTA- 
plasma samples by a commercial radioimmunoassay (Eiken 
Chemical Co.). The test kit uses a !&hly specific antiserum 
against alpha-h-atria1 natriurctic peptidc without extraction 
and a second antibody for the separation of the bound 
antic+ and the free fraction. Tlte normal range is 20 to 
65 pg/ml. 
Hasma norepinephrirre was measured according to a modi- 
fication of the high pressure liquid chromatography method 
of Eriksson and Pemn (21). The limit of quantification was 
- 15 pg/ml norepinephrine in plasma. The intraassay precision 
:~as ~5%. and the interassay precision was <IO% in a range 
from 100 to 2.W pg/ml. Reference range in our lahontory was 
IO0 to 300 pg/ml. 
Hemodynamk mcasurmeots. Standard right heart mea- 
surements wcrc performed using a thcrmodilution. four- 
channel Swan-Ganz flow-directed halloon-tipped catheter 
(Edwards Lahoratorier model WA-Y.1 I Hi7.5 F) connected to 
a Gould-Statham PLID pressure transducer (Gould Inc.). 
Cardiac outpl:t was calculated with a thermodilution computer 
( Baxter-Edwards, REF. I). A chest lead electrocardiogram was 
recorded continuously during the study period to obtain heart 
rate. Arterial blood pressure was measured by cuff. Hemody- 
namic indexes were calculated according to standard formulas. 
Statistid aamlysii. Continuous variables arc expressed as 
mean value 2 SEM. Univariate analyses were performed using 
the Student I test and one-way analysis of variance followed by 
Tukey’s multiple-range mmparison test. as appropriate. Cate- 
goric data were compared against II chi-square distribution. 
The Pearson’s correlation coeficient was calculated to assess 
correlation between data. To determine whether the levels of 
big endothelin-I seen in our patients with severe heart failure 
had independent prognostic significance or only reflected the 
importance of other factors, I7 variables, as listed below. were 
entered into a Cox proportional hazards regression analysis 
provided by the SA!3 procedure PHREG. Continuous rather 
than dichotomized variables were used in the Cox model. 
Because plasma norepinephrine levels were determined in 
Cliniralfarrrwx analyzed acre New York Heart Asxrintion 
functional cla5s. plasma MKlium cons:nlration and daily dose 
of captopril and furosemidc. Hmlttij!\namic fi~rurs wcrc left 
ventricular ejection fraction, heart rate. mean arterial blood 
prcnurc. right atrial pressure. mean pulmonary artery prcs- 
sure. pulmonary capillary wedge pressure. cardiac index. sys- 
temic vascular resistance index. pulmonary vascular rcsistancc 
index. N~~rrrul,urn~,~llucrrrrs wcrc plasma concentrations of hig 
endothclin-I. atrial natriuretic: ~ptkic and aldosterone and 
plasma rcnin iictivity. 
Stcpwisc Cox regressic%n analyses were done I) with pa- 
tients who survived and those who died. without those who 
undcrwcnt transplantation; and 2) uith patients *ho sunivcd 
and those who died. together uith them who underwent 
transplantation. Kaplan-Meicr sunival estimates and the Iog- 
r:rnk test were used to compare survival between groups: p < 
0.O.i was considered significant in all pnalyscs. 
Results 
Dcqraphic and clinical data. Functional class. left 
ventricular ejection fraction. crcatininc plasma levels. daily 
furoscmidc dose and plasma sodium levels differed signifi- 
cantly between sun&on and nonsurvivors as well as hetwecn 
survivors and transplant recipients (Table I). Of all stan- 
dard laboratory measurements. only plasma sodium levels 
dilfcred between nonsurvivon and transplant rrcipients. Daily 
angiotensinconverting enzyme inhibitor dose was similar in all 
groups. 
Bii endotklin-I ad ncmmbumural plasma levels. Plasma 
loels of big endothelin-I. atrial natriuretic peptidz and nor- 
cpinephrine differed significantly ktwecn survivors and non- 
sulvivon as wel! as between survivors and transplant recipi- 
ents. and plasma renin activity and aldosteronc differed 
ktween survivors and nunsurvivors only (Fig. I ). Respective 
neurohumordl variables were similar in nonsurvivors and 
transplant recipients. 
Hwicam- ts. All hemodynamic data ex- 
cept heart rate and systemic and pulmonary vascular resistance 
indexes differed significantly between survivors and nonsuti- 
I ~rs as well as hetwecn survivors and transplant recipients. but 
c,nly pulmonary vascular resistance index differed ktween 
nonsurvivors and survivors as well as between nonsurvivors and 
transplant recipients (Table 2). 
Nturobtoarrlp4sNlntls~qto~dharl 
trilmre. Plasma lmek of big endothelin- I. norepinephrine and 
plasma renin activity differed significantly ktween all func- 
tional classes (Fig. 2). Atrial natriuretic peptide differed k- 
tween functional classes II and III and between II and IV. and 
aldctsterone diffcrcd ktween classes II and IV only. 
comlrtiolrs brtwem big tsddbdia-1 piaau WmcemtIw 
tias ad dinkal, badyumk ad - data. 
Among clinical variables. plasma big endotk!in-I concentra- 
tions correlated significantly with functional class, daily furo- 
fraction and pulmonary vauular rcsi5tance indca (all p - 
tt.tYl(~l L \rhcrcas systemic vascular rcsistancc indca did ntlt 
<orrclatc uith hig cndothclin-I plasma Ir\:Is Significant 
c-urrclariuns wcrc alscl found hctwccn plasma Icvch of big 
cndothclin-I and atrial natriurctic pcptidc (p = O.(wK)I). 
norcpincphrinc (p = !LoOl) and plasrx renin activity (p = 
O.tiI)l) hut no1 with plasma aldostcronc ccnccntrations. 
Univrrialc and multivariate predictors of mortality. 
During the observation period Y patients died and 58 patients 
survived without B transplant for at Icas; I ycEr (Tablc 4). 
Twenty-sir paticnrs underwent transplantati,jr,. Scvcntecn cl:n- 
ical. ncurohumlbral and hcmodynamic variables (see Methods) 
cjhtained from 87 patients (5X survivors. 20 nonsulvivors; 
excluding 20 heart transplant recipients) and irom the study 
cohort as a whrllc (surxivors. nonsurvivom and tnnspiant 
recipicnty) wcrc analyzed using a univariatc Cox propxtional 
hazards model and jtcpwisc Cox regression multivariate anal- 
ysis (TabIr 5;. According to the rc&-“ion model. plasma big 
cndothclin provided indrpcndcnt prognostic information, its 
did functional class. Once thcw: variahlcs wcrc rntcrcd into tbc 
model. othet vnrlahh~s. including atrial natriurrtk peptide. 
f&xi ttr contriLutc to the prediction of survival. 
- or 
F&IV 1. Plasma cunccntrations of hig endothrlin-l (Big ET), atrial 
natriurctic pcptidc (ANP). norcpincphrinc. plasma renin activitv and 
aldosteruue in I-year survivors (open ban), transplanr rrci$cnts 
(Mekd bars) and nonsurvivors (crussktcbed bars). HTX = heart 
transplantation. l ‘*p < 0.0001. “p < 0.001 ~crsus I-year survivors. 
Results are mean value % SEM. 
semide requirement (both p = 0.0001) and serum sodium 
concentration (p = O.OOU2) (Table 3). Correlations with hem* 
dynzJnic variables were highly significant with respect to right 
atria! pressure, pulmonary capillary wedge pressure. mean 
pulmonary artery pressure. mean artciial blood pressure, 
stroke volume index, cardiac index, left ventricular cjertion 
Kaplan-Mcicr lifetime analysis. Survival rates. as evalu- 
ated hy a Kaplan-Meicr lifctimc analysis. were significantly 
lower in patients with bie cndothelin-I levels ~4.3 fmoUmt 
independently wher! transplant recipients were eicludcd from 
the analysis (Fig. 3. top) (p < 0.01) or included (Fig. 3. hottom) 
(p < I,.CWWll). 
Discussion 
In the prcwnt study. wc used a radtoimmunoa%say for big 
cndothclin-I to show that in patients with severe chronic heArt 
failure hascd on low lcf! ventricular cjcction iraction. cil,:llat- 
ing plasma levels of big cndothclin-I were associated Hith a 
p>or prognosis. 
Rationale for big l ndothelin-I determination in serret~ 
heart failure. Although clcvations of tmrrunorcactivc 
cndothclin-I in chronic heart failure have been reported in 
several studies (I I-14). WC, in cotmast to others. have cvalu- 
atcd circulating big cndothelin-1 as a prognostic marker based 
on the assumption that it may reflect endothelin ovetpoduc- 
tion more accurately than circulating endothclm-I. The C- 
terminal fragment of big endothelin-I is rcleasrd during the 
proteolytic step producing cndothelir-I. As with other pep 
tides with high biologic activity, endothclin-1 is rapidly cleared. 
and. in case of paracrine action, may never reach the circula- 
tion. Precursor elements without biologic activity often circu. 
late in higher concentration, integrate the seeretoty activity of 
cndoerine cells and open an analytic window. Also. by our 
mcthodologic approach, the spccility IO measure big endothe- 
lin-l was optimized and circumvented the problem of measur- 
irg a mixture of big endothelin-I and mature 2l-amino acid 
adothelin-I (20). In a previous study. we reported that higit 
circulating blood levels of big endothelin- I arc present in heart 
failure patients (15). Recentty. Wei et al. (16) repotted that the 
Tabk 2. Hcmodynamic Variahlcs III I13 Patient5 With Heart FJilurc Acajrding II) Clinical Outcome 
elev3fion of cndothelin-I in severe heart failure rcprcsents 
predominantly big cndothelir,-1 by separating the hiolcgic~lly 
dctivc 21-amino acid pcptidc endothehr:-I from the less hio- 
logically active prohormone big endothelil;-I. Moreover. in 
healthy individuals. mature endothelin-I cornpri<.cd the whnlc 
immunoreactivc endothelin-I fraction. which means that C:I- 
ca+ating big cndothe!in-l was exclusively detected ia sz.~rc 
heart failure patients (16). 
Potential patbophysiolagir signifieaarc Oc inmrsed big 
rndotk)ia-1 levels. A numhcr of CnJothclin’s properties 
could mediate the characteristic ‘qmptoms of heart failure. 
for instqnre. the pcriphcnl hypopelfusion and rcdu,:cd vaso- 
dilatory reserve that are associated with a progressively de- 
creased functional capacity (22.23). We can only speculate on 
the relative palhophysiologic signrficancc of elevated big 
endothclin-1 levels compared to levels of th: mature and 
biologically active form. Biologic actions of increased big 
endothelin-1 in plasma could occur at sites distant from big 
endothelin-I production hecause the endothelinconverting 
enzyme is a ubiquitous enzyme. According to the severity of 
neart failure. plasma concentrations of big cndothelin-I in- 
creased in parallel with abliai natriuretic peptidc and norepi- 
nephrine concentrations. both hormones with established pre- 
dictive value in heart failure. Rcnin system activity was also 
included in the analysis, although patients were on captopril 
treatment. This decision was based on the findings of Packer et 
al. (24). who reported a g& response to captopril in d 
subgroup of patients with heart failure and low plasma renin 
activity. These patients were characterized hy considerable 
reactive hyperreninemia after captopril. Similar IO atrial natri- 
uretic peptide. which is believed to reflect the overall activity of 
vasoeonstrictive systems (S), big endothelin-I plasma concen- 
trations might also have the potential IO reflea otherwise 
hidden neurohumoral dir&n. Big endothelin-I levels come 
lated with tilling pressures and pulmonary vascular resistance 
levels. It is tempting IO interpret this result in favor of a specific 
role of eodothelin-l in producing right ventricular failure in 
patients with knmun low left ventricular ejection fractions, but 
the exact mechanism is uncxtain (lO.lJ). Al:hough a signifi- 
cant iu,rrclation cGst+ hetwecn all these variables and big 
endothelin-I plasma concentrations in advanced heart failure 
psiients in our study. the rclationshlp may not be causal. Thus. 
the role played by big endothclin-1 in the progression of the 
dkdw remains ln he ctucidated. 
Factors iaflncneirtg 5i.g mdolhtlin-I plasma kvcls in se- 
vere hrl failmrt. Little clinical information is available re- 
garding a change in endothelin levels after converting enzyme 
inhibition in heart failure patients. In the patients taking part 
in the CONSENSL’S II study. in whom endothelin-I determi- 
llation in the subacute phase of myocdtdial infarction was 
fcrunJ to predict survival after acute myocardial infarction. 
cnalapril appeared to influence the relation between plasma 
endo!hclin-I levels and mortality (IY). We recently observed 
that long-tclm treatmen! of xvere heart failure patients with 
aggressive enalapril doses as high as 40 m&day was associated 
with a significant reduction in plasma big endothclin-I levels 
after 6 months. but big endothelin-I levels were no longer 
significantly different from baseline after 1 year (25). In 
contrast to theoretical c0nsiderations (26). exogenous angio- 
tensin infusions do not increase cndothelin-I plasma levels in 
healthy volunteers (27). This observation iq non??al subjects. 
however. may ilot 5e relevant for the interrelation between 
endothelin and angiotensin in severe heart failure patients. In 
theory. besides inc: cased production of big endothelin- I. par- 
ticularly in severe heart faibre. a decreased conversion rate Gf 
big endothelin-I to mature endothelin-I and a decreased 
clearance of endothelin across deranged renal and pulmonary 
circulations may also result in elevation of big endothelin-I 
plasma levels (28-30). 
U&atbns aftbe SW. The o&ervatiun that levels of big 
endothelin-1 provide independent prognostic information has 
to be interpreted with caution based on the following compli- 
cating factors. 
1. We measured big endtihelin-I levels at the time of initial 
asscssmcnt of hemodynamics after referral of the patients so as 
to obtain prognostic information before patients were further 
Fwrc 2 Pl;lrma conccntratians of hig cndothelin-I (Big El’). ncrrcpi- 
nephrine. atrial naturirtic peptidc (ANP). plasma renin activitv and 
aldosteronc in patients according to New York Heart Asst&rtion 
(NYHA) functiunal class. Opce bars = functional class II: hrkhed 
b8rs = functiona! clas Ill; erosshatebed bars = functional class IV. 
“‘p -z O.OOOI versus NW York Heatl &uGatkjn It. #p i O.OUOI 
versus New York Hean Arwriation Ill. l *p < (I.01 versus New York 
Heart hociation II. mp < O.Mll v~rws New York Hcan Asuri;llon 
Ill. l p < 0.05 versti New York Hean Association II. Results are mean 
value z SEM. 
managed in our center. Thus. patients were taking captopril in 
varying dosages at study entry. During subsequent follow-up. 
patients received toutine conventional heart failure therapy as 
commonly used at the time of the study. As mentioned in the 
Methods section. big cndothclin-I and other ncurohunloral 
plasma lcvcls wcrc not availahlc to the clinician and did not 
influcncc pat&l medication. Thcrcforc. bawd on our stuJy 
dcaign. no conclusion can bc drawn whcthet suppression of big 
cndothclin-I is :tlw) a marker for a favorable response to 
angiotcnsin-converting enzyme inhihition or about the prog 
nostic role of big cndothctin-I after optimized therapy. 
2. Plasma norepincphrine lcvcls were not mcasurcd in all 
patients. thus precluding analysis of the relative sensitivity of 
big endothclin- I compared to this well cstdhlishcd ncurohu- 
moral marker of discasc severity and prognosis. However. 
Gottlich ct al. (5). who previously established the indepcndcnt 
prognostic signilicancc or atrial natriurctic peptide in patients 
with chronic heart failure and left ventricular ejection fractions 
~4Wl,, demonsirated that plasma norepincphrinc was no 
longer a significant predictor of survival as soon as atrial 
natriureilc pcptide was entered into the Cox model. WC found 
tha: atrlal natriurctic peptidc was no longer a significant 
predictor of survival in our patients with chronic heart failtire 
and left ventricular ejection fractions <20% as soon as big 
cndothelin-I was entered into the Cox model. Ba.sed on these 
observations, it is unlikely that the predictive power of big 
cndothelin-I levels in severe heart failure is similar to that of 
norcpinephrine. 
3. Last. the absence of exercise data may also be considered 
to limit the interpretation of our results. because a low peak 
oxygen consumption is an established risk factor in the geIWil 
heart failure population (4). Currently there is no 4dencr 
that big rndothclin-I lcvcls can substitute for exercise testing. 
These two may be testing independent prupncnti; features. 
Htnvever. if the device to medaure peak oxygen consumption is 
not available. or if an cxer&e lesl cannot be performed 
because of prohlcms other than those arising from heart 
failure, plasma big endothelin-I Icvels may he another 
powertul p:ognostic aid for the clinician to identify high risk 
patients. 
ConAusions. From a clinical point of view. objccti\r prog- 
mastic inffirmation gained in :bddition to routine prx-cdurcs 
appears to he particularly helpful in patients with advanced 
heart failure who may have only mild or modcrate symptoms 
despite considemhle ventricular dysfunction. Our findings sup 
gest that in thew patienis plasma big endothclin-I concentra- 
tions arc strcmply related to sunival and appear In predict 
I-year mortality better than invasive resting hemodynamic 
variahlcs and plasma Icvels of atrial nmriureric pepridc. a 
m 3. Top. Kaplan-Meier analysis showing cumulative rates of 
survival in R7 paM’icnts with severe chrome heart failure (fig one-year 
s~tiors ys. ?9 nonsurvivors) slralified into two group according 111 
hig endolhelin-I (Big ET) plasma cnnccnlrarion. Patients with plasma 
hig cndothclin-I levels ~4.3 fmollml diffcrcd significantly from pa. 
licnts with lower hig endotklin-I ronccmralionc (p r: 0.1~1). Bottom, 
Kaplan-Mcicr analysis showing cumuhtivc raks of su~~ival in I13 
paknts with severe chronic kan failure (SK one-year survivor5 vs. 19 
nonsurvivors and 26 transplanr rkpirnts) stratified into ho groups 
according IO big cndothelin-I plasma concxfitration. Patients with 
plasma big endothelin-I levels >4.3 fmoUml dilkred significantly from 




endothetin- I plasma concekations- (p < 
indepcndcnt ncurohumoral prognostic 
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